Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PADRE (Pan-DR-binding epitope) is a synthetic 13-amino acid peptide with the sequence AKFVAAWTLKAAA. It functions as a universal MHC class II-restricted T-helper epitope designed to bind with high affinity to a broad range of human HLA-DR alleles (covering over 90% of the human population) as well as mouse I-A and I-E molecules. By binding to these MHC class II molecules on antigen-presenting cells, PADRE activates CD4+ T-helper cells, which provide essential signals for the induction and maintenance of robust CD8+ cytotoxic T lymphocyte (CTL) responses. PADRE is frequently incorporated into cancer vaccines and infectious disease vaccine candidates to overcome HLA polymorphism and enhance the immunogenicity of target antigens, particularly those that are weakly immunogenic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PADRE.